Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.1,2 The approval by the European Commission was